Supporting emerging biotechs on their journey from clinical development to commercialization, Inizio Biotech is a strategic partner offering best-in-class solutions to guide, validate, and inspire the decisions that maximize asset value.
As one of five specialist business units within Inizio, Inizio Biotech provides emerging biotechs with a single point of contact to access best-in-class services across Inizio’s key business units, Advisory, Medical, MarComms, and Engagement. Its team of subject matter experts has the therapeutic area and modality expertise to help mitigate risks and maximize value at every opportunity.
Uniting over 11,500 experts and 750 PhDs across 35 countries, Inizio Biotech provides specialist support to the top 30 pharmaceutical companies. It has also supported 100+ biotech companies from clinical development through to product launch.
Its team of specialists understands the unique and daunting challenges facing emerging companies and offers expertise across:
– Clinical development strategy
– Medical affairs, such as patient recruitment for clinical trials
– Commercial strategy
– Evidence, pricing, and access
– Brand and creative development
– Healthcare provider, patient, and payer engagement
Inizio’s membership with MassBio signals its dedication to connecting with and supporting life science innovators, providing a depth and breadth of expertise and scalable services to support biotech companies from phase I to phase III of their clinical development journey.
Jason McKenna, Global President at Inizio Biotech, commented: “Emerging biotech are increasingly looking to us for the specific expertise and tailored solutions that help maximize the value of their assets throughout the product lifecycle. Our partnership with MassBio will provide a platform to collaborate and share the knowledge and expertise found across Inizio to achieve better patient and business outcomes.”
For more information on how Inizio Biotech can help your emerging biotech maximize the value of its asset, get in touch: